Effect of sulfobutyl ether-β-cyclodextrin on bioavailability of insulin glargine and blood glucose level after subcutaneous injection to rats

International Journal of Pharmaceutics

Volumn 419, Issue 1-2, 2011, Pages 71-76

  Uehata, Keiko ^a   Anno, Takayuki ^a   Hayashida, Kayoko ^a   Motoyama, Keiichi ^a   Hirayama, Fumitoshi ^b   Ono, Naomi ^c   Pipkin, James D ^c   Uekama, Kaneto ^b   Arima, Hidetoshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SOJO UNIVERSITY   (Japan)

^c CyDex LC   (United States)

Author keywords

Diabetes; Insulin glargine; Subcutaneous injection; Sulfobutyl ether cyclodextrin; Sustained release system

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; INSULIN GLARGINE; TYROSINE;

ANIMAL EXPERIMENT; ARTICLE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; ENZYME DEGRADATION; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE;

ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; INJECTIONS, SUBCUTANEOUS; INSULIN, LONG-ACTING; MALE; RATS; RATS, WISTAR; SOLUBILITY;

EID: 80053566809     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.07.018     Document Type: Article

References (25)

1. J.F. Blickle, J. Doucet, T. Krummel, and T. Hannedouche Diabetic nephropathy in the elderly Diabetes Metab. 33 2007 S40 S55
2. J. Brange, L. Andersen, E.D. Laursen, G. Meyn, and E. Rasmussen Toward understanding insulin fibrillation J. Pharm. Sci. 86 1997 517 525 (Pubitemid 27203397)
3. M.E. Brewster, M.S. Hora, J.W. Simpkins, and N. Bodor Use of 2-hydroxypropyl-β-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs Pharm. Res. 8 1991 792 795
4. J. Goldman, and F.H. Carpenter Zinc binding, circular dichroism, and equilibrium sedimentation studies on insulin (bovine) and several of its derivatives Biochemistry 13 1974 4566 4574
5. S. Havelund, A. Plum, U. Ribel, I. Jonassen, A. Volund, J. Markussen, and P. Kurtzhals The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin Pharm. Res. 21 2004 1498 1504 (Pubitemid 39149667)
6. E.S. Horton Can newer therapies delay the progression of type 2 diabetes mellitus? Endocr. Pract. 14 2008 625 638
7. K. Ikeda, K. Uekama, and M. Otagiri Inclusion complexes of β-cyclodextrin with antiinflammatory drugs fenamates in aqueous solution Chem. Pharm. Bull. 23 1975 201 208
8. T. Irie, and K. Uekama Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation J. Pharm. Sci. 86 1997 147 162 (Pubitemid 27078377)
9. P. Kurtzhals Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir Int. J. Obes. Relat. Metab. Disord. 28 2004 S23 S28
10. H.K. Leiros, B.O. Brandsdal, O.A. Andersen, V. Os, I. Leiros, R. Helland, J. Otlewski, N.P. Willassen, and A.O. Smalas Trypsin specificity as elucidated by LIE calculations, X-ray structures, and association constant measurements Protein Sci. 13 2004 1056 1070 (Pubitemid 38429227)
11. B. Patterson, A.V. Fields, and R.P. Shannon New insights into myocardial glucose metabolism: surviving under stress Curr. Opin. Clin. Nutr. Metab. Care 12 2009 424 430
12. A. Rolla Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety Am. J. Med. 121 2008 S9 S19
13. R.J. Schilling, and A.K. Mitra Degradation of insulin by trypsin and α-chymotrypsin Pharm. Res. 8 1991 721 727
14. R. Simo, E. Carrasco, M. Garcia-Ramirez, and C. Hernandez Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy Curr. Diabetes Rev. 2 2006 71 98 (Pubitemid 44082952)
15. V.J. Stella, and R.A. Rajewski Cyclodextrins: their future in drug formulation and delivery Pharm. Res. 14 1997 556 567 (Pubitemid 27220271)
16. L. Szente, and J. Szejtli Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development Adv. Drug Deliv. Rev. 36 1999 17 28 (Pubitemid 29074474)
17. S. Tavornvipas, F. Hirayama, S. Takeda, H. Arima, and K. Uekama Effects of cyclodextrins on chemically and thermally induced unfolding and aggregation of lysozyme and basic fibroblast growth factor J. Pharm. Sci. 95 2006 2722 2729 (Pubitemid 46093178)
18. K. Tokihiro, H. Arima, S. Tajiri, T. Irie, F. Hirayama, and K. Uekama Improvement of subcutaneous bioavailability of insulin by sulphobutyl ether β-cyclodextrin in rats J. Pharm. Pharmacol. 52 2000 911 917
19. K. Tokihiro, T. Irie, F. Hirayama, and K. Uekama Mass spectroscopic evidence on inhibiting effect of maltosyl-β-cyclodextrin on insulin self-association Pharm. Sci. 2 1996 519 522 (Pubitemid 28121883)
20. K. Tokihiro, T. Irie, and K. Uekama Potential use of maltosyl-β- cyclodextrin for inhibition of insulin self-association in aqueous solution Pharm. Sci. 1 1995 49 53
21. K. Tokihiro, T. Irie, and K. Uekama Varying effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin in aqueous solution Chem. Pharm. Bull. 45 1997 525 531 (Pubitemid 27150218)
22. K. Uekama Design and evaluation of cyclodextrin-based drug formulation Chem. Pharm. Bull. 52 2004 900 915 (Pubitemid 41701863)
23. K. Uekama, F. Hirayama, and T. Irie Cyclodextrin drug carrier systems Chem. Rev. 98 1998 2045 2076 (Pubitemid 128633447)
24. K. Uekama, and M. Otagiri Cyclodextrins in drug carrier systems Crit. Rev. Ther. Drug Carrier Syst. 3 1987 1 40 (Pubitemid 17231927)
25. F. Wang, J.M. Carabino, and C.M. Vergara Insulin glargine: a systematic review of a long-acting insulin analogue Clin. Ther. 25 2003 1541 1577 (discussion 1539-1540) (Pubitemid 36801936)